TYPE: Late Breaking Abstract TOPIC: Practice Management and Administration PURPOSE: PURPOSE: to analyze compliance and clinical response in a group of patients with severe asthma (SA) and chronic rhinosinusitis with nasal polyps (CRwNP) performing self-administration of biologic therapy at home. METHODS: METHODS: we enrolled patients with severe asthma (step 5 of GINA Guidelines) and CRwNP receiving biologic therapy in the ambulatory care of the Pneumology department (ASL 5, La Spezia. They switch to self-administration at home. At the first injection in the clinic, patients were educated to self-administration. They could communicate to a dedicated nurse any adverse event or question. Asthma Control Test (ACT), Severe Asthma Questionnaire (SAQ), and Sino-Nasal Outcome Test (SNOT-22) were performed at baseline and after three months. RESULTS: RESULTS: 10 patients treated with biologics (4 with mepolizumab, 3 dupilumab, 2 omalizumab, 1 benralizumab) had self-administration at home. All patients performed it during the scheduled date. At baseline the mean ACT score was 8.8, SAQ 177.9, SNOT-22 was 34. At three months ACT score was 23.7, SAQ 340.3, SNOT-22 was 6. CONCLUSIONS: CONCLUSIONS: self-administration of biologics at home is safe, patients had good compliance and an improvement of symptoms. CLINICAL IMPLICATIONS: CLINICAL IMPLICATIONS: self-administration at home is well tolerated, with an improvement of SA and CRwNP symptoms. Our study suggests the importance of dedicated pathways in the management of chronic diseases at home to shift the burden of care to the outpatient setting. DISCLOSURE: No significant relationships. KEYWORD: SEVERE ASTHMA, SELF ADMINISTRATION, QUALITY OF LIFE